NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Ensysce Biosciences, Inc. (ENSC) Stock Analysis

Ensysce Biosciences, Inc. (ENSC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ENSC

$0.52

+$0.02 (+4.29%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ENSC with… →

ENSC Key Statistics

As of Oct 21, 2026
Trading
Open
$0.49
Previous Close
$0.50
Day's Range
0.49–0.53
52-Week Range
0.23–2.33
Volume
290.11K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.02
Valuation
Market Cap
$10.12M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.25
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.47
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$10.18M
Profit marginThe share of revenue left as profit after all costs and taxes.
−280.48%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
19.46M
1-Year Return
−77.59%
Dividend and dates
Avg Volume
13.97M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ENSC closed at $0.52, −77.59% over 1 year.

Ensysce Biosciences, Inc. (ENSC) has a market capitalization of $10.12M.

In fiscal 2025, ENSC reported revenue of $0.00.

ENSC Stock Return by Calendar Year

Ensysce Biosciences, Inc. (ENSC) return since Mar 2018: what $10,000 became

1 year
$10,000 $2,241
−77.59%
5 years
$10,000 $0.59
−99.99%
Since Mar 2018
$10,000 $0.15
−99.998%

If you had invested $10,000 in Ensysce Biosciences, Inc. (ENSC) at the close on March 14, 2018, the earliest close on record here, it would have been worth $0.15 at the close on October 21, 2026: −99.998% in total, −72.47% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−43.48%
2025−88.70%
2024−48.81%
2023−88.22%
2022−99.20%
2021−62.20%
2020+19.34%
2019+6.11%
2018 (partial year)+2.83%

As of October 21, 2026.

ENSC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$10.18M—
2024$0.00−$7.99M—
2023$0.00−$10.61M—
2022$0.00−$24.17M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$10.24M−$10.18M—
2024$0.00—−$6.73M−$7.99M—
2023$0.00—−$10.72M−$10.61M—
2022$0.00—−$24.22M−$24.17M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ENSC Valuation vs Biotechnology Median

Median of 608 stocks
MetricENSCBiotechnology medianvs median
P/S ratio2.2513.300.2x the median
Profit margin−280.48%−38.31%242.2 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Ensysce Biosciences, Inc. (ENSC) carries a market capitalisation of $10.12M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 8.

The 52-week range on file runs from $0.23 to $2.33. The most recent close on file for ENSC is $0.52, dated October 21, 2026. That is +$0.02 (+4.29%) against the previous close. The latest close sits 126.09% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $10.18M. The reported profit margin is −280.48%. That is 242.2 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −2.47.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 2.25. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −77.59%. Across 5 years the annualized return works out at −85.73%. Beta against the wider market is reported at 1.02. Daily returns over the trailing 8 years annualize to a volatility of 145.6%.

Growth & Income

The record shows no dividend for ENSC.

So far in 2026 the total return is −43.48%. Across the complete calendar years on file, 2020 returned +19.34% and 2022 returned −99.20%. Of the 7 complete calendar years on file, 2 finished higher.

Peer Comparison

Ensysce Biosciences, Inc. (ENSC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ensysce Biosciences, Inc. ENSC $10.12M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Ensysce Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Visit website →